<DOC>
	<DOCNO>NCT00152698</DOCNO>
	<brief_summary>The retinal vasculature morphologically functionally related cerebral vessel due common origin internal carotid artery . A recent study demonstrate endothelium-dependent vasodilation retinal vasculature impair patient essential hypertension , strong risk factor stroke . Furthermore , AT1-receptor blockade demonstrate improve retinal endothelium-dependent vasodilation hypertensive patient . Hypercholesterolemia also risk factor ischemic stroke impairment endothelial function observe various vascular bed hypercholesterolemic patient , include coronary forearm vasculature . Whether endothelial function retinal vasculature impair patient hypercholesterolemia yet investigate . In patient stroke , AT1-receptor blockade angiotensin-converting enzyme inhibition beneficial effect clinical outcome . Alterations endothelial function cerebral vasculature might one pathogenetic factor beneficial clinical outcome . To address issue , present study design test hypothesis endothelium-dependent vasodilation retinal vasculature impaired hypercholesterolemic patient endothelial function improve AT1-receptor blockade .</brief_summary>
	<brief_title>Effect Irbesartan Endothelial Function Retinal Vasculature Patients With Hypercholesterolemia</brief_title>
	<detailed_description>see</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Male patient age 1865 year LDLcholesterol &gt; = 130mg/dl Male healthy control subject age 1865 year All kind secondary hyperlipidemia . Advanced damage vital organ ( grade III IV retinopathy ) Lipidlowering drug ( include lipid lower dietary supplement food additive ) within last 4 week History serious hypersensitivity reaction AT1receptor blocker Actual anamnestic alcohol drug abuse . Smokers exsmokers &lt; 1 year . Patients Diabetes mellitus ( oral medication insulin ) . Patients arterial fibrillation AVBlock ( IIÂ° ) . Patients anamnestic myocardial infarction . Patients instable angina pectoris include EcGaberrations cardiac insufficiency NYHA III IV . History malignancy ( unless document diseasefree period exceed 10 year present ) exception basal cell carcinoma skin History allograft transplantation Patients anaphylaxis know therapy resistance use test matter Therapy approve concomitant medication , participation clinical study within 4 week precede treatment start . Disease interfere pharmacodynamics pharmacokinetics study drug . Liver kidney disease SGOT , GPT , gGT , AP , bilirubin creatinin 200 % standard . Patients , sufficiently compliant , patient , capable willing appear control visit . Presumed risk transmission HIV hepatitis via blood proband</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>